|Bid price||19.75||Open price||20.00|
|Ask price||20.00||Prev close||19.88|
Register now for FREE live Vernalis share prices, Vernalis stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vernalis Level 2 Data, indepth research tools and investor commentary for Vernalis (VER) and other London Stock Exchange equities.
Register now for FREE Vernalis share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB00B3Y5L754|
|Activites||Vernalis plc (formerly British Biotech) is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.||Index||n/a|
|Latest Share Price (p)||19.88||Net Gearing (%)||2.43|
|Market Capitalisation (£m)||104.64||Gross Gearing (%)||8.68|
|Shares in issue (m)||526.37||Debt Ratio||1.96|
|P/E Ratio||-6.21||Debt-to-Equity Ratio||0.21|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||1.10|
|Dividend Yield (%)||0.00||Price to book value||1.02|
|Dividend cover (x)||0.00||ROCE (%)||-14.60|
|Earning per share (p)||-3.20||EPS Growth (%)||-128.57|
|52 week high / low||56.63 / 19.75||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
RNS Number : 5935D Vernalis PLC 28 April 2017 TOTAL VOTING RIGHTS VERNALIS PLC (the "Company") 28 April 2017 Vernalis plc (LSE: VER) announces that the Company's total issued share capital at the date of this announcement is 526,386,480 ordinary...
Vernalis and Servier announce the achievement of two research milestones and one clinical milestone in their oncology drug discovery collaboration, triggering a total payment of €2m to Vernalis. Vernalis and Servier's partnership has been successfully running for 10 years. The collaboration...
Story provided by StockMarketWire.com
Register now for FREE Vernalis company news
This is for 2008 -9 (2007 was a year with great hopes and hype, equals a sp about 50p) Reality now is a sp about 4p Yet despite a drug failure ( was it?), they have some products that look interesting - not earth-shattering but a decent pipeline AND some CASH - "wow"! the only Q in my mind: Is...
Surely the answer from FDA is going to be yes!
Register now for FREE Vernalis share price discussions